Related Experiment Video
Updated: Feb 21, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.6K
Hepatitis C infection and chemotherapy toxicity
Amy Ly1, Heather H Cheng2,3, Laura Alwan1
11 Department of Pharmacy, University of Washington Medicine/Seattle Cancer Care Alliance, Seattle, WA, USA.
Summary
Managing chemotherapy toxicity in patients with hepatitis C viral infection requires careful attention. Recommendations include increased monitoring, dose adjustments, and growth factor support, even with normal liver function tests.
Area of Science:
- Oncology
- Hepatology
- Pharmacology
Background:
- Limited guidance exists for managing chemotherapy toxicity in patients with hepatitis C viral infection (HCV).
- Hepatitis C poses unique challenges in cancer treatment due to potential liver dysfunction and drug interactions.
Observation:
- Four cases of solid organ tumor patients with HCV experienced severe or unexpected chemotherapy toxicities.
- These toxicities occurred despite normal baseline liver function tests in some instances.
Findings:
- Increased laboratory monitoring for chemotherapy-induced toxicities is recommended.
- Consider initial chemotherapy dose reductions for palliative regimens.
- Prophylactic growth factor support may be beneficial.
- Treating active hepatitis C viral infection before chemotherapy is advisable when feasible.
Implications:
- These findings suggest a need for proactive management strategies in HCV-infected cancer patients undergoing chemotherapy.
- Implementing these recommendations may improve patient safety and treatment outcomes.
- Further research is warranted to establish definitive guidelines for this patient population.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
270
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
270
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
663
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
663
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
223
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
223
02:49Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
01:30Drug toxicity: Drug–Drug Interaction
54
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
54
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
810
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
810